SITE006-0064

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-05-18

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-07-31 (study day 68); relationship: N

severe serious assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-26 (study day 94); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-10 (study day 109); relationship: not assessed

severe serious assessed

Grade 4 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-10 (study day 109); relationship: N; serious criteria: life-threatening

Data queries

No data queries.